• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 509690 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1416739277 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1416739277 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Top 3 Companies in the Biotechnology Industry With the Highest Future Earnings Growth (GHDX, ACOR, LGND)

Published on Thu, 05/30/2013 - 10:31
By Peter Chu

Below are the three companies in the Biotechnology industry with the highest future earnings growth. The growth of earnings per share (next fiscal year estimated vs. current fiscal year estimated) is important to gauge future profitability and relative value. Higher EPS growth generally justifies higher earnings multiples.

Genomic Health (NASDAQ:GHDX) is highest with future earnings growth of 126.8%. Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer. The Company's diagnostic services provide information on the likelihood of disease recurrence and response to certain types of therapy.

Genomic Health (NASDAQ:GHDX) defies analysts with a current price ($37.54) 4.4% above its average consensus price target of $35.88. The stock should find initial support at its 50-day moving average (MA) of $31.25 and further support at its 200-day MA of $30.86.

Acorda Therapeutics (NASDAQ:ACOR) is next with future earnings growth of 119.9%.

Finishing up the top three is Ligand Pharmaceuticals (NASDAQ:LGND), with future earnings growth of 94.9%.

By Peter Chu
pchu@fnno.com

Latest News from FNNO

Post Earnings Update: International Pape...

When International Paper (NYSE:IP) reported earnings two weeks ago on November 4th, 201 ...

Protective Life Earnings Review: 19 Days...

Two weeks ago on November 3rd, 2014 Protective Life (NYSE:PL) reported earnings and ana ...

Earnings Look Back: Estee Lauder Is Up 1...

18 days ago, on November 4th, 2014, Estee Lauder (NYSE:EL) reported its earnings. Anal ...

Delek US Holdings Earnings Review: 17 Da...

When Delek US Holdings (NYSE:DK) reported earnings two weeks ago on November 5th, 2014, ...

Earnings Look Back: Stifel Financial Is ...

When Stifel Financial (NYSE:SF) reported earnings two weeks ago on November 6th, 2014, ...

Post Earnings Update: Dean Foods Has Cli...

A week ago on November 10th, 2014 Dean Foods (NYSE:DF) reported earnings and analysts, ...

Earnings Look Back: CF Industries Is Up ...

When CF Industries (NYSE:CF) reported earnings two weeks ago on November 5th, 2014, ana ...

Spectra Energy Earnings Hindsight: Up 0....

When Spectra Energy (NYSE:SE) reported earnings 17 days ago on November 5th, 2014, anal ...